Skip to main content
Top
Published in: Acta Diabetologica 4/2013

01-08-2013 | Original Article

Correlation of insulin resistance, beta cell function and insulin sensitivity with serum sFas and sFasL in newly diagnosed type 2 diabetes

Authors: Hemant Kumar, Manish Mishra, Surabhi Bajpai, Deepa Pokhria, Awadhesh Kumar Arya, Rakesh Kumar Singh, Kamlakar Tripathi

Published in: Acta Diabetologica | Issue 4/2013

Login to get access

Abstract

Pancreatic beta cell dysfunction and reduced insulin sensitivity are fundamental factors associated with glucotoxicity, lipotoxicity and oxidative stress in type 2 diabetic patients (T2DM). Diabetic milieu can induce apoptosis in several types of cells. The aim of present study was to compare circulating soluble apoptotic markers (sFas and sFas-L) with HOMA-IR, HOMA-%S, HOMA-%B in the serum of newly diagnosed T2DM and healthy subjects. For this study, 94 T2DM and 60 healthy subjects were enroled and evaluated for various parameters. Biochemical quantifications were performed with Syncron CX5 auto-analyzer. The levels of serum sFas-L, TNF-α and IL-6 were estimated by flowcytometry. The fasting serum insulin and sFas quantified by ELISA. HOMA-IR, HOMA-%S and HOMA-%B were calculated with HOMA calculator v2.2.2. The levels of TC, TG, LDL-C, VLDL-C were augmented and HDL declined significantly (P < 0.001) in diabetics. The levels of serum insulin, TNF-α, IL-6, sFas, HOMA-IR were raised (P < 0.001) and sFas-L, HOMA-%S and HOMA-%B were decreased significantly (P < 0.001) in T2DM subjects than healthy. In diabetics, serum sFas was positively correlated with HOMA-IR (r = 0.720, P < 0.001) and negatively with HOMA-%B (r = −0.642, P < 0.001) significantly while serum sFasL was negatively correlated with HOMA-IR (r = −0.483, P < 0.001) and positively with HOMA-%B (r = 0.466, P < 0.001) significantly. Further, the multivariate stepwise regression analysis shows that HOMA-IR contributes significantly to the variance of sFas and sFasL. Our findings suggest that the pancreatic beta cell dysfunction along with increased insulin resistance appears to be associated with apoptotic markers.
Literature
1.
go back to reference International Diabetes Federation (2009) Diabetes Atlas 4th edn International Diabetes Federation (2009) Diabetes Atlas 4th edn
2.
go back to reference Reaven G (2004) The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am 33:283–330CrossRef Reaven G (2004) The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am 33:283–330CrossRef
3.
go back to reference Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR (1996) Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci 93:12490–12495PubMedCrossRef Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR (1996) Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci 93:12490–12495PubMedCrossRef
4.
go back to reference Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J Clin Inves 100:2158–2169CrossRef Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J Clin Inves 100:2158–2169CrossRef
5.
go back to reference Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM (2002) Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 40:937–943PubMedCrossRef Abbasi F, Brown BW Jr, Lamendola C, McLaughlin T, Reaven GM (2002) Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 40:937–943PubMedCrossRef
6.
go back to reference Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716PubMedCrossRef Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716PubMedCrossRef
7.
go back to reference Rewers M, Zaccaro D, D’Agostino R, Haffner S, Saad MF, Selby JV et al (2004) Insulin sensitivity, insulinemia, and coronary artery disease: the insulin resistance atherosclerosis study. Diabetes Care 27:781–787PubMedCrossRef Rewers M, Zaccaro D, D’Agostino R, Haffner S, Saad MF, Selby JV et al (2004) Insulin sensitivity, insulinemia, and coronary artery disease: the insulin resistance atherosclerosis study. Diabetes Care 27:781–787PubMedCrossRef
8.
go back to reference Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S et al (2004) Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension 43:1324–1331PubMedCrossRef Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S et al (2004) Insulin resistance and hypertension: the insulin resistance atherosclerosis study. Hypertension 43:1324–1331PubMedCrossRef
9.
go back to reference Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drrexel H (2005) The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90:5698–5703PubMedCrossRef Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drrexel H (2005) The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90:5698–5703PubMedCrossRef
10.
go back to reference Sandler S, Bendtzen K, Eizirik DL, Strandell E, Welsh M, Welsh N (1990) Metabolism and beta-cell function of rat pancreatic islets exposed to human interleukin-1beta in the presence of high glucose concentration. Immunol Lett 26:245–252PubMedCrossRef Sandler S, Bendtzen K, Eizirik DL, Strandell E, Welsh M, Welsh N (1990) Metabolism and beta-cell function of rat pancreatic islets exposed to human interleukin-1beta in the presence of high glucose concentration. Immunol Lett 26:245–252PubMedCrossRef
11.
go back to reference Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A et al (2001) Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 50:1683–1690PubMedCrossRef Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A et al (2001) Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 50:1683–1690PubMedCrossRef
14.
go back to reference Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F et al (1996) Fas ligand in human serum. Nat Med 2:317–322PubMedCrossRef Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F et al (1996) Fas ligand in human serum. Nat Med 2:317–322PubMedCrossRef
15.
go back to reference Guillot R, Bringuier AF, Porokhov B, Guillausseau PJ, Feldmann G (2001) Increased levels of soluble Fas in serum from diabetic patients with neuropathy. Diabetes Metab 27:315–321PubMed Guillot R, Bringuier AF, Porokhov B, Guillausseau PJ, Feldmann G (2001) Increased levels of soluble Fas in serum from diabetic patients with neuropathy. Diabetes Metab 27:315–321PubMed
16.
go back to reference American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl. 1):S62–S69CrossRef American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl. 1):S62–S69CrossRef
18.
go back to reference Cai L, Li W, Wang GW, Guo LP, Jiang YC, Kang YJ (2002) Hyperglycemia induced apoptosis in mouse myocardium-mitochondrial cytochrome c-mediated caspase-3 activation pathway. Diabetes 51:1938–1948PubMedCrossRef Cai L, Li W, Wang GW, Guo LP, Jiang YC, Kang YJ (2002) Hyperglycemia induced apoptosis in mouse myocardium-mitochondrial cytochrome c-mediated caspase-3 activation pathway. Diabetes 51:1938–1948PubMedCrossRef
19.
go back to reference Romeo G, Liu WL, Asnaghi V, Kern TS, Lorenzi M (2002) Activation of nuclear factor-kappa B induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51:2241–2248PubMedCrossRef Romeo G, Liu WL, Asnaghi V, Kern TS, Lorenzi M (2002) Activation of nuclear factor-kappa B induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51:2241–2248PubMedCrossRef
20.
go back to reference Faradji RN, Havari E, Chen Q, Gray J, Tornheim K, Corkey BE et al (2001) Glucose-induced toxicity in insulin-producing pituitary cells that coexpress GLUT2 and glucokinase-implications for metabolic engineering. J Biol Chem 276:36695–36702PubMedCrossRef Faradji RN, Havari E, Chen Q, Gray J, Tornheim K, Corkey BE et al (2001) Glucose-induced toxicity in insulin-producing pituitary cells that coexpress GLUT2 and glucokinase-implications for metabolic engineering. J Biol Chem 276:36695–36702PubMedCrossRef
21.
go back to reference Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC et al (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759–1762PubMedCrossRef Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC et al (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759–1762PubMedCrossRef
22.
go back to reference Stalder M, Pometta D, Suenram A (1981) Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia 21:544–548PubMed Stalder M, Pometta D, Suenram A (1981) Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia 21:544–548PubMed
23.
go back to reference Pykalisto OJ, Smith PH, Brunzell JD (1975) Determinants of human adipose tissue lipoprotein lipase: effect of diabetes and obesity on basal- and diet-induced activity. J Clin Invest 56:1108–1117PubMedCrossRef Pykalisto OJ, Smith PH, Brunzell JD (1975) Determinants of human adipose tissue lipoprotein lipase: effect of diabetes and obesity on basal- and diet-induced activity. J Clin Invest 56:1108–1117PubMedCrossRef
24.
go back to reference Sadur CN, Yost TJ, Eckel RH (1984) Insulin responsiveness of adipose tissue lipoprotein lipase is delayed but preserved in obesity. J Clin Endocrinol Metab 59:1176–1182PubMedCrossRef Sadur CN, Yost TJ, Eckel RH (1984) Insulin responsiveness of adipose tissue lipoprotein lipase is delayed but preserved in obesity. J Clin Endocrinol Metab 59:1176–1182PubMedCrossRef
25.
go back to reference Golay A, Zech L, Shi MZ, Chiou YA, Reaven GM, Chen YD (1987) High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab 65:512–518PubMedCrossRef Golay A, Zech L, Shi MZ, Chiou YA, Reaven GM, Chen YD (1987) High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab 65:512–518PubMedCrossRef
26.
go back to reference Gual P, Le Marchand-Brustel Y, Tanti JF (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie (Paris) 87:99–109CrossRef Gual P, Le Marchand-Brustel Y, Tanti JF (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie (Paris) 87:99–109CrossRef
27.
go back to reference Zick Y (2001) Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol 11:437–441PubMed Zick Y (2001) Insulin resistance: a phosphorylation-based uncoupling of insulin signaling. Trends Cell Biol 11:437–441PubMed
28.
go back to reference Tanti JF, Gremeaux T, Van Obberghen E, Le Marchand-Brustel Y (1994) Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 269:6051–6057PubMed Tanti JF, Gremeaux T, Van Obberghen E, Le Marchand-Brustel Y (1994) Serine/threonine phosphorylation of insulin receptor substrate 1 modulates insulin receptor signaling. J Biol Chem 269:6051–6057PubMed
29.
go back to reference Aguirre V, Uchida T, Yenush L, Davis R, White MF (2000) The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J Biol Chem 275:9047–9054PubMedCrossRef Aguirre V, Uchida T, Yenush L, Davis R, White MF (2000) The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J Biol Chem 275:9047–9054PubMedCrossRef
30.
go back to reference Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE et al (2001) A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signalling through insulin receptor substrate-1. Proc Natl Acad Sci 98:4640–4645PubMedCrossRef Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE et al (2001) A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signalling through insulin receptor substrate-1. Proc Natl Acad Sci 98:4640–4645PubMedCrossRef
31.
go back to reference Gual P, Gremeaux T, Gonzalez T, Le Marchand-Brustel Y, Tanti JF (2003) MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307, 612 and 632. Diabetologia 46:1532–1542PubMedCrossRef Gual P, Gremeaux T, Gonzalez T, Le Marchand-Brustel Y, Tanti JF (2003) MAP kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor substrate-1 on serine residues 307, 612 and 632. Diabetologia 46:1532–1542PubMedCrossRef
32.
go back to reference Bouzakri K, Roques M, Gual P, Espinosa S, Guebre-Egziabher F, Riou JP et al (2003) Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52:1319–1325PubMedCrossRef Bouzakri K, Roques M, Gual P, Espinosa S, Guebre-Egziabher F, Riou JP et al (2003) Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes 52:1319–1325PubMedCrossRef
33.
go back to reference Engelman JA, Berg AH, Lewis RY, Lisanti MP, Scherer PE (2000) Tumor necrosis factor-α mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3–L1 adipocytes. Mol Endocrinol 14:1557–1569PubMedCrossRef Engelman JA, Berg AH, Lewis RY, Lisanti MP, Scherer PE (2000) Tumor necrosis factor-α mediated insulin resistance, but not dedifferentiation, is abrogated by MEK1/2 inhibitors in 3T3–L1 adipocytes. Mol Endocrinol 14:1557–1569PubMedCrossRef
34.
go back to reference Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985–15991PubMedCrossRef Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985–15991PubMedCrossRef
35.
go back to reference Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434–5446PubMedCrossRef Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434–5446PubMedCrossRef
36.
go back to reference Rui L, Yuan M, Frantz D, Shoelson S, White MF (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394–42398PubMedCrossRef Rui L, Yuan M, Frantz D, Shoelson S, White MF (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394–42398PubMedCrossRef
37.
go back to reference Shi H, Cave B, Inouye K, Bjorbaek C, Flier JS (2006) Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 55:699–707PubMedCrossRef Shi H, Cave B, Inouye K, Bjorbaek C, Flier JS (2006) Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance. Diabetes 55:699–707PubMedCrossRef
38.
go back to reference Rotter V, Nagaev I, Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3–L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777–45784PubMedCrossRef Rotter V, Nagaev I, Smith U (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3–L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777–45784PubMedCrossRef
39.
go back to reference Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M (2003) Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311:372–379PubMedCrossRef Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M (2003) Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311:372–379PubMedCrossRef
40.
go back to reference Warne JP (2003) Tumour necrosis factor-α: a key regulator of adipose tissue mass. J Endocrinol 177:351–355PubMedCrossRef Warne JP (2003) Tumour necrosis factor-α: a key regulator of adipose tissue mass. J Endocrinol 177:351–355PubMedCrossRef
41.
go back to reference Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF (2007) Interleukin-1 beta-induced insulin resistance in adipocytes through downregulation of insulin receptor substrate-1 expression. Endocrinol 148:241–251CrossRef Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF (2007) Interleukin-1 beta-induced insulin resistance in adipocytes through downregulation of insulin receptor substrate-1 expression. Endocrinol 148:241–251CrossRef
42.
go back to reference Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52:2169–2181PubMedCrossRef Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52:2169–2181PubMedCrossRef
43.
go back to reference Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O et al (2005) Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115:3494–3505PubMedCrossRef Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O et al (2005) Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115:3494–3505PubMedCrossRef
Metadata
Title
Correlation of insulin resistance, beta cell function and insulin sensitivity with serum sFas and sFasL in newly diagnosed type 2 diabetes
Authors
Hemant Kumar
Manish Mishra
Surabhi Bajpai
Deepa Pokhria
Awadhesh Kumar Arya
Rakesh Kumar Singh
Kamlakar Tripathi
Publication date
01-08-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0307-8

Other articles of this Issue 4/2013

Acta Diabetologica 4/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.